A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.
The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
The company defends its cancer strategy, and says it's not a me-too developer.
Luminice-203 yields its first topline data, but where are all the patients?